大环内酯类抗生素代谢工程的研究进展

14-16元环的大环内酯类抗生素(Macrolide antibiotics,MA)是临床上重要的抗感染药物.随着细菌耐药性的不断增加,迫切需要研发出新型MA来应对耐药菌.通过MA与核糖体靶点的相互作用可以指导MA的定向优化,结合快速发展的代谢工程方法可以高效获得所需的MA衍生物.近30年来,代谢工程在改造MA的生物合...

Advances in metabolic engineering of macrolide antibiotics

14- to 16-membered macrolide antibiotics (MA) are clinically important anti-infective drugs. With the rapid emergence of bacterial resistance, there is an urgent need to develop novel MA to counter drug-resistant bacteria. The targeted optimization of MA can be guided by analyzing the interaction between the MA and its ribosomal targets, and the desired MA derivatives can be obtained efficiently when combining with the rapidly developed metabolic engineering approaches. In the past 30 years, metabolic engineering approaches have shown great advantages in engineering the biosynthesis of MA to create new derivatives and to improve their production. These metabolic engineering approaches include modification of the structural domains of the polyketide synthase (PKS) and post-PKS modification enzymes as well as combinatorial biosynthesis. In addition, the R&D (including the evaluation of its antimicrobial activities and the optimization through metabolic engineering) of carrimycin, a new 16-membered macrolide drug, are described in details in this review.